Timothy P. Noyes is a distinguished biotechnology leader with more than 30 years of experience in the pharmaceutical and life sciences sectors. Holding a Ph.D. in Biochemistry from the Massachusetts Institute of Technology (MIT) and an MBA from the Wharton School of the University of Pennsylvania, Noyes began his career at Pfizer, where he advanced from research scientist to Vice President of Drug Discovery, spearheading the development of three FDA-approved oncology therapeutics that generated over $5 billion in cumulative revenue. His expertise in translational medicine and strategic partnerships propelled him to executive roles at several biotech startups, including a successful exit as COO of BioVance Therapeutics, which was acquired by a major pharmaceutical firm in 2012. As Chief Executive Officer of JADE Biosciences Inc. from 2016 to 2023, Noyes transformed the company from an early-stage venture into a clinical-stage innovator focused on novel gene therapies for neurodegenerative diseases. Under his leadership, JADE secured over $250 million in funding from top-tier venture capital firms and strategic alliances with Eli Lilly and Novartis, advancing two pipeline candidates into Phase II trials. Noyes's strategic vision emphasized agile R&D and patient-centric innovation, resulting in breakthrough designations from the FDA and multiple peer-reviewed publications in top journals like Nature Biotechnology. Post his tenure at JADE, Noyes continues to influence the industry as a board advisor to emerging biotech firms and a venture partner at a leading life sciences investment fund. His achievements have earned him recognition as a "Biotech Visionary" by BioSpace and induction into the Healthcare Businesswomen's Association Hall of Fame, underscoring his enduring impact on therapeutic innovation and business growth.